PRKCB and experimental autoimmune encephalomyelitis: In the experimental autoimmune encephalomyelitis (EAE) mouse model, a model of brain inflammatory disease, KK antibody applied after the onset of neurological symptom significantly attenuated the signs of EAE in mice with a remarkable reduction of BBB disruption and brain inflammation.[229] In addition, activation of protein kinase Cβ (PKCβ) augmented expression of a broad range of inflammatory mediators,[230] while inhibition of PKCβ by LY‐317615 stabilized the BBB in EAE mice.[231]